Currently, the COVID-19 pandemic, which began at the end of 2019, is still prevailing
worldwide in 2021. Although the mortality rate of COVID-19 itself is a big issue, there is also …

Background and aim Current observational studies have compared the effectiveness and
safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Background/Objectives: Contradictory results have been reported regarding the influence of
obesity on the prognosis of atrial fibrillation (AF). The present study aimed to explore the …

Atrial fibrillation (AF) is considered the most common sustained cardiac arrhythmia, and it is
associated with a significant risk of adverse events, especially ischemic stroke. Oral …

Background There are conflicting data on outcomes in patients with atrial fibrillation treated
with non–vitamin K oral anticoagulants across varying body mass index (BMI). We …

背景华法林在心房颤动患者的抗凝治疗中具有重要地位, 而其抗凝治疗稳定性是评价药物疗效的
重要指标, 现有研究均显示华法林抗凝治疗稳定性的达标率较低, 对于如何有效计算抗凝治疗 …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Abstract Background The 2021 International Society on Thrombosis and
Haemostasis'(ISTH) recommends standard doses of apixaban and rivaroxaban regardless …

Objetivo Caracterizar el tiempo en rango terapéutico (TTR) y estimar la tasa de incidencia
de complicaciones (PTIRc) en adultos con protocolo de warfarina. Diseño Cohorte …